Current emerging and investigational drugs for the treatment of chronic hand eczema

Julia Cheng, Paola Facheris, Benjamin Ungar, Emma Guttman-Yassky

Research output: Contribution to journalReview articlepeer-review

11 Scopus citations


Introduction: Chronic hand eczema (CHE) is a highly prevalent, burdensome condition associated with functional impairment. Currently, topical therapeutics are the mainstay of CHE management. However, many cases are refractory to existing topical therapeutics, and the few existing systemic options are often limited in efficacy and by their side effect profiles. Areas covered: Following a brief overview of CHE pathogenesis and existing treatments, this review will outline the mechanisms and available data on emerging and investigational drugs currently being studied in clinical trials for the treatment of CHE. Expert opinion: Immunomodulatory drugs such as topical and systemic JAK inhibitors and Th2-targeting antibodies such as dupilumab are currently under investigation for CHE treatment, with early promise. Management of CHE will likely move toward more targeted treatments through clinical trials and away from broad immunosuppressants such as cyclosporine and methotrexate, which have previously been investigated for CHE and have more side effects. In coming years, CHE patients may benefit from a wider range of both topical and systemic therapeutics that target immune pathways relevant to the various CHE subtypes.

Original languageEnglish
Pages (from-to)843-853
Number of pages11
JournalExpert Opinion on Investigational Drugs
Issue number8
StatePublished - 2022


  • AFX5931
  • chronic hand eczema
  • delgocitinib
  • dupilumab
  • gusacitinib
  • roflumilast
  • ruxolitinib


Dive into the research topics of 'Current emerging and investigational drugs for the treatment of chronic hand eczema'. Together they form a unique fingerprint.

Cite this